Advertisement
Australia markets close in 1 hour 18 minutes

  • ALL ORDS

    8,036.30
    +84.00 (+1.06%)
     

  • ASX 200

    7,763.70
    +81.30 (+1.06%)
     

  • AUD/USD

    0.6606
    -0.0019 (-0.29%)
     

  • OIL

    78.63
    +0.15 (+0.19%)
     

  • GOLD

    2,330.00
    -1.20 (-0.05%)
     

  • Bitcoin AUD

    96,032.04
    -1,081.62 (-1.11%)
     

  • CMC Crypto 200

    1,362.28
    +49.65 (+3.78%)
     

  • AUD/EUR

    0.6133
    -0.0013 (-0.21%)
     

  • AUD/NZD

    1.0992
    -0.0028 (-0.25%)
     

  • NZX 50

    11,793.84
    -26.94 (-0.23%)
     

  • NASDAQ

    18,093.57
    +202.77 (+1.13%)
     

  • FTSE

    8,213.49
    +41.34 (+0.51%)
     

  • Dow Jones

    38,852.27
    +176.59 (+0.46%)
     

  • DAX

    18,175.21
    +173.61 (+0.96%)
     

  • Hang Seng

    18,420.38
    -157.92 (-0.85%)
     

  • NIKKEI 225

    38,769.34
    +533.27 (+1.39%)
     

Agenus to Participate in B. Riley Securities' Oncology Investor Conference

Agenus Inc.
·1-min read

LEXINGTON, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Dr. Jennifer Buell, President and COO of Agenus, and Dr. Steven O’Day, CMO of Agenus, will participate in B. Riley Securities’ Oncology Investor Conference on January 20-21, 2021.

Agenus Fireside Chat
Dr. Jennifer Buell
Thursday, January 21, 2021
10:30am – 11:00am
The live webcast can be accessed via this link: https://www.webcaster4.com/Webcast/Page/2433/39550

Dr. Jennifer Buell and Dr. Steven O’Day will also participate in a panel discussion on novel immunotherapies. Please contact your B. Riley representative for details.

Replays for each event will be available on the Events & Presentations page of the Agenus website at https://investor.agenusbio.com/events-and-presentations.

ADVERTISEMENT

About Agenus
Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its AgenTus Therapeutics subsidiary), and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and Twitter.

Contact:
Agenus Inc.
Caroline Bafundo
212-994-8209
Caroline.Bafundo@agenusbio.com